Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1Phase 1/2 1

Status

Recruiting 128Active not recruiting 122Completed 54Not yet recruiting 16Terminated 11Withdrawn 3Suspended 2

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Lymphoid 3

Conditions

Recurrence 2Lymphoma, Large B-Cell, Diffuse 2Lymphoma, Follicular 1Burkitt Lymphoma 1

Interventions

pembrolizumab 19Magnetic Resonance Spectroscopy 14Specimen Handling 13Cyclophosphamide 11fludarabine 10Radiotherapy 9Biopsy 9atezolizumab 7Nivolumab 7Radiation 6Gemcitabine 5fludarabine phosphate 4aldesleukin 4Prednisone 4Paclitaxel 4Etoposide 4Cytarabine 4Cisplatin 4Carboplatin 4Blood Specimen Collection 4Bevacizumab 4ALT-803 4venetoclax 3lenvatinib 3avelumab 3X-Rays 3Vincristine 3Surveys and Questionnaires 3Rituximab 3Phantoms, Imaging 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Withdrawn × Rituximab × 1 year × Clear all
NCT06313996 2026-03-18

A Study to Evaluate the Efficacy and Safety of Liso-cel Compared to Standard of Care in Adults With Relapsed or Refractory Follicular Lymphoma

Juno Therapeutics, Inc., a Bristol-Myers Squibb Company

Phase 3 Withdrawn
Lymphoid

Lymphoma, Follicular, Recurrence

NCT04285268 2026-01-30

Rituximab, Venetoclax, and Bortezomib for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Rutgers, The State University of New Jersey

Phase 2 Withdrawn
Lymphoid

Burkitt Lymphoma, Lymphoma, Large B-Cell, Diffuse

NCT04607772 2025-10-03

Study of Selinexor in Combination With Backbone Treatments or Novel Therapies In Participants With Relapsed or Refractory (RR) Diffuse Large B-Cell Lymphoma (DLBCL)

Karyopharm Therapeutics Inc

Phase 1/2 Withdrawn
Lymphoid

Recurrence, Lymphoma, Large B-Cell, Diffuse

Data powered by HemOnc (CC BY 4.0) Colophon âš¡